Chronic high dose l-dopa treatment does not alter the levels of dopamine D-1, D-2 or D-3 receptor in the striatum of normal monkeys: an autoradiographic study

Zeng, B.-Y.; Pearce, R. K. B.; MacKenzie, G. M.; Jenner, P.
September 2001
Journal of Neural Transmission;Sep2001, Vol. 108 Issue 8/9, p925
Academic Journal
Summary. To assess the role of dopamine receptors in the genesis of dyskinesia, we have used quantitative autoradiography to determine the effect of chronic l-dopa administration on dopamine D-1 (using [3H]SCH 23390), D-2 (using [3H]spiperone) and D-3 (using [3H]7-OH-DPAT) receptor binding levels in the striatum of dyskinetic or non-dyskinetic monkeys. Total and subregional striatal analysis showed no difference in D-1, D-2 or D-3 receptor binding in the caudate and putamen between monkeys receiving high dose l-dopa treatment with marked dyskinesia and those without dyskinesia compared to untreated animals. It thus appears unlikely that changes in dopamine receptor expression are a primary cause of l-dopa induced dyskinesia. Rather, a functional dissociation of D-2 receptor coupling to co-expressed enkephalin/adenosine-2a receptor activity in the striato-GPe indirect pathway may be more important in the development or expression of l-dopa-induced involuntary movements.


Related Articles

  • The Impact of COMT-inhibition on Gastrointestinal Levodopa Absorption in Patients with Parkinson's Disease. Müller, Thomas // Clinical Medicine Insights: Therapeutics;2010, Issue 2, p155 

    Abstract: The drug Levodopa (LD) is an efficient compound for the treatment of patients with Parkinson's disease (PD). Its short half life generates plasma behaviour of LD with peaks and troughs. Therefore, following the LD transport into the brain and the conversion to dopamine, an alternating...

  • Functional and autoradiographic characterization of dopamine D2 -like receptors in the guinea pig heart. Gomez, Maria de Jesus; Rousseau, Guy; Nadeau, Reginald; Berra, Roberto; Flores, Gonzalo; Suarez, Jorge // Canadian Journal of Physiology & Pharmacology;Jun2002, Vol. 80 Issue 6, p578 

    Dopamine receptors include the D[sub1] -(D[sub1] and D[sub5] subtypes) and D[sub2]-like (D[sub2] ,D[sub3] , and D[sub4] subtypes) families. D[sub1]-like receptors are positively and D[sub2]-like receptors negatively coupled to the adenylyl cyclase. Dopamine D[sub2] -like (D[sub4] subtype)...

  • Visualisation of the cortical dopamine D3 receptors in alcoholics and controls with human whole-hemisphere autoradiography. Tupala, Erkki; Hall, Håkan; Tiihonen, Jari // Psychopharmacology;Sep2005, Vol. 181 Issue 2, p412 

    Presents a study that compared dopamine receptors in the anterior cingulate and frontal and temporal cortices of nine type 1 alcoholics, eight type 2 alcoholics and ten healthy controls with human whole-hemisphere autoradiography. Procedure of the study; Visualization of dopamine receptors;...

  • The clinical spectrum of levodopa-induced motor complications. Hametner, E.; Seppi, K.; Poewe, W. // Journal of Neurology;Nov2010, Vol. 257, p268 

    fter more than 40 years of clinical use, levodopa (LD) still remains the gold standard for symptomatic efficacy in Parkinson's disease (PD). However, long-term treatment with LD is often complicated by the development of various types of motor response oscillations as well as drug-induced...

  • Dopamine Receptors and Parkinson's Disease. Hisahara, Shin; Shimohama, Shun // International Journal of Medicinal Chemistry;2011, p1 

    Parkinson's disease (PD) is a progressive extrapyramidal motor disorder. Pathologically, this disease is characterized by the selective dopaminergic (DAergic) neuronal degeneration in the substantia nigra. Correcting the DA deficiency in PD with levodopa (Ldopa) significantly attenuates the...

  • Levodopa.  // Reactions Weekly;9/9/2006, Issue 1118, p13 

    The article presents a case report of a 74-year-old woman and a 65-year-old man who developed permanent mandible dyskinesia with forward and lateral movements after starting treatment with levodopa for Parkinson's disease. During the levodopa challenge, their dyskinesia persisted with no...

  • The Role of the Subthalamic Nucleus in L-DOPA Induced Dyskinesia in 6- Hydroxydopamine Lesioned Rats. Aristieta, Asier; Azkona, Garikoitz; Sagarduy, Ainhoa; Miguelez, Cristina; Ruiz-Ortega, José Ángel; Sanchez-Pernaute, Rosario; Ugedo, Luisa; Cookson, Mark R. // PLoS ONE;Aug2012, Vol. 7 Issue 8, Special section p1 

    L-DOPA is the most effective treatment for Parkinson's disease (PD), but prolonged use leads to disabling motor complications including dyskinesia. Strong evidence supports a role of the subthalamic nucleus (STN) in the pathophysiology of PD whereas its role in dyskinesia is a matter of...

  • In vivo affinity of [18F]fallypride for striatal and extrastriatal dopamine D2 receptors in nonhuman primates. Slifstein, Mark; Dah-Ren Hwang; Yiyun Huang; NingNing Guo; Sudo, Yasuhiko; Narendran, Raj; Talbot, Peter; Laruelle, Marc // Psychopharmacology;2004, Vol. 175 Issue 3, p274 

    Presents a study which determined the in vivo affinity of [18F]fallypride for striatal and extrastriatal dopamine D2 receptors in nonhuman primates. Measurement of the in vivo affinity of [18F]fallypride for D2 receptors; Comparison between the in vivo affinity of [18F]fallypride in striatal...

  • Characterization of in vivo pharmacokinetic properties of the dopamine D1 receptor agonist DAR-0100A in nonhuman primates using PET with [11C] NNC112 and [11C] raclopride. Slifstein, Mark; Suckow, Raymond F; Javitch, Jonathan A; Cooper, Thomas; Lieberman, Jeffrey; Abi-Dargham, Anissa // Journal of Cerebral Blood Flow & Metabolism;Jan2011, Vol. 31 Issue 1, p293 

    DAR-0100A, the active enantiomer of dihydrexidine, is a potent dopamine D1 agonist under investigation for treatment of cognitive impairment and negative symptoms of schizophrenia. We measured the dose-occupancy relationship for DAR-0100A at D1 receptors using positron emission tomography (PET)...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics